Latest News about EDIT
Recent news which mentions EDIT
What 5 Analyst Ratings Have To Say About Editas Medicine
November 03, 2022
Tickers
EDIT
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022
September 29, 2022
From Benzinga
From Benzinga
Down 35% This Year, Is This Small-Cap Stock a Buy?
July 21, 2022
From Motley Fool
The 3 Leaders of the Gene Editing Revolution
July 08, 2022
From InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
July 08, 2022
From InvestorPlace
From Motley Fool
BMO Initiates Coverage On This Gene Editing Spearhead
June 17, 2022
From Benzinga
From Benzinga
From InvestorPlace
16 Stocks Moving in Tuesday's Pre-Market Session
June 07, 2022
From Benzinga
Cathie Wood Is Selling Gene Editing Stocks. Here’s Why.
June 02, 2022
From InvestorPlace
Why Editas Medicine's Shares Fell 28.9% This Week
May 13, 2022
From Motley Fool
From Benzinga
From Motley Fool
Editas Medicine's EDIT-301 receives FDA Rare Pediatric Disease designation for Beta Thalassemia
April 26, 2022
Tickers
EDIT
From Benzinga
3 Ominous Reasons to Avoid This Biotech Pioneer
April 19, 2022
From Motley Fool
From Motley Fool
Who Benefits From Amazon's Stock Split?
March 16, 2022
From Motley Fool
Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents
March 01, 2022
Tickers
EDIT
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.